3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase NA
1
Phase EARLY_PHASE1
1
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
174
INDUSTRY
33
NIH
16
OTHER_GOV
1
NETWORK
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Interventions
Cisplatin
118
Radiotherapy
114
Cyclophosphamide
93
Paclitaxel
84
Gemcitabine
74
Carboplatin
67
Filgrastim
60
Doxorubicin
57
Vincristine
56
Etoposide
56
Docetaxel
56
Fluorouracil
51
Cytarabine
41
Prednisone
40
Methotrexate
40
Leucovorin
39
Dexamethasone
37
Capecitabine
36
Irinotecan
35
Rituximab
29
Oxaliplatin
28
Granulocyte Colony-Stimulating Factor
27
Cetuximab
26
Bevacizumab
26
durvalumab
24
Temozolomide
24
Radiotherapy, Intensity-Modulated
24
Peripheral Blood Stem Cell Transplantation
24
Magnetic Resonance Spectroscopy
24
Surgical Procedures, Operative
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
NETWORK
×
venetoclax
×
Clear all
NCT05628623
2024-07-03
ERASE
Eastern Cooperative Oncology Group
Phase 2
Not yet recruiting
184 enrolled